Cargando…
Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment
Targeted radionuclide therapy (TRT) and immunotherapy are rapidly growing classes of cancer treatments. Basic, translational, and clinical research are now investigating therapeutic combinations of these agents. In comparison to external beam radiation therapy (EBRT), TRT has the unique advantage of...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865370/ https://www.ncbi.nlm.nih.gov/pubmed/36678756 http://dx.doi.org/10.3390/pharmaceutics15010128 |
_version_ | 1784875820679954432 |
---|---|
author | Kerr, Caroline P. Grudzinski, Joseph J. Nguyen, Thanh Phuong Hernandez, Reinier Weichert, Jamey P. Morris, Zachary S. |
author_facet | Kerr, Caroline P. Grudzinski, Joseph J. Nguyen, Thanh Phuong Hernandez, Reinier Weichert, Jamey P. Morris, Zachary S. |
author_sort | Kerr, Caroline P. |
collection | PubMed |
description | Targeted radionuclide therapy (TRT) and immunotherapy are rapidly growing classes of cancer treatments. Basic, translational, and clinical research are now investigating therapeutic combinations of these agents. In comparison to external beam radiation therapy (EBRT), TRT has the unique advantage of treating all disease sites following intravenous injection and selective tumor uptake and retention—a particularly beneficial property in metastatic disease settings. The therapeutic value of combining radiation therapy with immune checkpoint blockade to treat metastases has been demonstrated in preclinical studies, whereas results of clinical studies have been mixed. Several clinical trials combining TRT and immune checkpoint blockade have been initiated based on preclinical studies combining these with EBRT and/or TRT. Despite the interest in translation of TRT and immunotherapy combinations, many questions remain surrounding the mechanisms of interaction and the optimal approach to clinical implementation of these combinations. This review highlights the mechanisms of interaction between anti-tumor immunity and radiation therapy and the status of basic and translational research and clinical trials investigating combinations of TRT and immunotherapies. |
format | Online Article Text |
id | pubmed-9865370 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98653702023-01-22 Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment Kerr, Caroline P. Grudzinski, Joseph J. Nguyen, Thanh Phuong Hernandez, Reinier Weichert, Jamey P. Morris, Zachary S. Pharmaceutics Review Targeted radionuclide therapy (TRT) and immunotherapy are rapidly growing classes of cancer treatments. Basic, translational, and clinical research are now investigating therapeutic combinations of these agents. In comparison to external beam radiation therapy (EBRT), TRT has the unique advantage of treating all disease sites following intravenous injection and selective tumor uptake and retention—a particularly beneficial property in metastatic disease settings. The therapeutic value of combining radiation therapy with immune checkpoint blockade to treat metastases has been demonstrated in preclinical studies, whereas results of clinical studies have been mixed. Several clinical trials combining TRT and immune checkpoint blockade have been initiated based on preclinical studies combining these with EBRT and/or TRT. Despite the interest in translation of TRT and immunotherapy combinations, many questions remain surrounding the mechanisms of interaction and the optimal approach to clinical implementation of these combinations. This review highlights the mechanisms of interaction between anti-tumor immunity and radiation therapy and the status of basic and translational research and clinical trials investigating combinations of TRT and immunotherapies. MDPI 2022-12-30 /pmc/articles/PMC9865370/ /pubmed/36678756 http://dx.doi.org/10.3390/pharmaceutics15010128 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kerr, Caroline P. Grudzinski, Joseph J. Nguyen, Thanh Phuong Hernandez, Reinier Weichert, Jamey P. Morris, Zachary S. Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment |
title | Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment |
title_full | Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment |
title_fullStr | Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment |
title_full_unstemmed | Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment |
title_short | Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment |
title_sort | developments in combining targeted radionuclide therapies and immunotherapies for cancer treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865370/ https://www.ncbi.nlm.nih.gov/pubmed/36678756 http://dx.doi.org/10.3390/pharmaceutics15010128 |
work_keys_str_mv | AT kerrcarolinep developmentsincombiningtargetedradionuclidetherapiesandimmunotherapiesforcancertreatment AT grudzinskijosephj developmentsincombiningtargetedradionuclidetherapiesandimmunotherapiesforcancertreatment AT nguyenthanhphuong developmentsincombiningtargetedradionuclidetherapiesandimmunotherapiesforcancertreatment AT hernandezreinier developmentsincombiningtargetedradionuclidetherapiesandimmunotherapiesforcancertreatment AT weichertjameyp developmentsincombiningtargetedradionuclidetherapiesandimmunotherapiesforcancertreatment AT morriszacharys developmentsincombiningtargetedradionuclidetherapiesandimmunotherapiesforcancertreatment |